Roche Holding AG (RHHBY)
32.18
-0.46
(-1.41%)
USD |
OTCM |
Mar 18, 16:00
Roche Cash from Financing (TTM): -4.652B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.652B |
June 30, 2023 | -12.30B |
December 31, 2022 | -16.87B |
June 30, 2022 | -18.19B |
December 31, 2021 | -14.34B |
June 30, 2021 | -11.21B |
December 31, 2020 | -10.11B |
June 30, 2020 | -15.49B |
December 31, 2019 | -14.22B |
June 30, 2019 | -12.12B |
December 31, 2018 | -10.80B |
June 30, 2018 | -9.545B |
December 31, 2017 | -11.27B |
June 30, 2017 | -11.77B |
December 31, 2016 | -10.26B |
June 30, 2016 | -9.525B |
December 31, 2015 | -10.99B |
June 30, 2015 | -4.135B |
Date | Value |
---|---|
December 31, 2014 | -4.780B |
June 30, 2014 | -11.35B |
December 31, 2013 | -15.68B |
June 30, 2013 | -14.86B |
December 31, 2012 | -10.37B |
June 30, 2012 | -11.06B |
December 31, 2011 | -12.21B |
June 30, 2011 | -13.17B |
December 31, 2010 | -17.07B |
June 30, 2010 | -21.32B |
December 31, 2009 | -13.93B |
June 30, 2009 | -7.268B |
December 31, 2008 | -9.013B |
June 30, 2008 | -8.869B |
December 31, 2007 | -4.377B |
June 30, 2007 | -3.709B |
December 31, 2006 | -2.992B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-18.19B
Minimum
Jun 2022
-4.652B
Maximum
Dec 2023
-12.95B
Average
-13.26B
Median
Cash from Financing (TTM) Benchmarks
Novartis AG | -14.28B |
Pfizer Inc | 26.07B |
Gilead Sciences Inc | -5.125B |
Eli Lilly and Co | 3.496B |
CRISPR Therapeutics AG | 62.66M |